Dixie‐Lee Esseltine

5.8k total citations · 1 hit paper
12 papers, 1.8k citations indexed

About

Dixie‐Lee Esseltine is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Dixie‐Lee Esseltine has authored 12 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Oncology and 6 papers in Hematology. Recurrent topics in Dixie‐Lee Esseltine's work include Multiple Myeloma Research and Treatments (6 papers), Protein Degradation and Inhibitors (4 papers) and Viral-associated cancers and disorders (3 papers). Dixie‐Lee Esseltine is often cited by papers focused on Multiple Myeloma Research and Treatments (6 papers), Protein Degradation and Inhibitors (4 papers) and Viral-associated cancers and disorders (3 papers). Dixie‐Lee Esseltine collaborates with scholars based in United States, France and Italy. Dixie‐Lee Esseltine's co-authors include Paul G. Richardson, Robert Z. Orlowski, Jessica Anderson, Kenneth C. Anderson, Sagar Lonial, Thomas C. Shea, Stephanie Stahl, Peter J. Elliott, Roberto Guerciolini and Steven Novick and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Dixie‐Lee Esseltine

12 papers receiving 1.7k citations

Hit Papers

Phase I Trial of the Prot... 2002 2026 2010 2018 2002 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies
    2002 586 citations Robert Z. Orlowski, Thomas E. Stinchcombe et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dixie‐Lee Esseltine United States 11 1.2k 1.1k 817 285 190 12 1.8k
Sarah Waheed United States 22 1.4k 1.2× 1.7k 1.5× 935 1.1× 219 0.8× 162 0.9× 69 2.0k
Halyna Pylypenko Czechia 11 736 0.6× 747 0.7× 672 0.8× 389 1.4× 341 1.8× 29 1.3k
Annamaria Brioli Italy 20 1.3k 1.1× 1.8k 1.6× 954 1.2× 255 0.9× 167 0.9× 72 2.2k
Martin Kropff Germany 26 2.1k 1.7× 2.5k 2.3× 1.7k 2.0× 368 1.3× 183 1.0× 69 3.1k
Andrew Cakana United States 20 1.4k 1.2× 1.5k 1.3× 948 1.2× 299 1.0× 62 0.3× 48 1.9k
William Deraedt United States 15 1.7k 1.4× 2.2k 2.0× 1.5k 1.9× 410 1.4× 199 1.0× 56 2.7k
Anuj Mahindra United States 17 703 0.6× 918 0.8× 477 0.6× 227 0.8× 95 0.5× 56 1.2k
Leonard T. Heffner United States 21 856 0.7× 996 0.9× 784 1.0× 561 2.0× 464 2.4× 86 1.8k
Huaibao Feng United States 13 859 0.7× 1.1k 1.0× 796 1.0× 229 0.8× 110 0.6× 30 1.4k
Andrea Freeman United States 12 787 0.7× 1.1k 0.9× 586 0.7× 221 0.8× 100 0.5× 15 1.4k

Countries citing papers authored by Dixie‐Lee Esseltine

Since Specialization
Citations

This map shows the geographic impact of Dixie‐Lee Esseltine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dixie‐Lee Esseltine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dixie‐Lee Esseltine more than expected).

Fields of papers citing papers by Dixie‐Lee Esseltine

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dixie‐Lee Esseltine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dixie‐Lee Esseltine. The network helps show where Dixie‐Lee Esseltine may publish in the future.

Co-authorship network of co-authors of Dixie‐Lee Esseltine

This figure shows the co-authorship network connecting the top 25 collaborators of Dixie‐Lee Esseltine. A scholar is included among the top collaborators of Dixie‐Lee Esseltine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dixie‐Lee Esseltine. Dixie‐Lee Esseltine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Reece, Donna, Ute Hegenbart, Vaishali Sanchorawala, et al.. (2014). Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood. 124(16). 2498–2506. 56 indexed citations
2.
Solh, Melhem, Richard I. Fisher, André Goy, et al.. (2013). Herpes zoster complicating bortezomib therapy of relapsed/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trials. Leukemia & lymphoma. 54(10). 2185–2189. 4 indexed citations
3.
Zinzani, Pier Luigi, Nuriet K. Khuageva, Huaqing Wang, et al.. (2012). Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial. Journal of Hematology & Oncology. 5(1). 67–67. 17 indexed citations
4.
Coiffier, Bertrand, Evgenii A. Osmanov, Xiaonan Hong, et al.. (2011). Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. The Lancet Oncology. 12(8). 773–784. 81 indexed citations
5.
Reece, Donna, Ute Hegenbart, Vaishali Sanchorawala, et al.. (2011). Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 118(4). 865–873. 123 indexed citations
6.
Richardson, Paul G., Wanling Xie, Constantine S. Mitsiades, et al.. (2009). Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy. Journal of Clinical Oncology. 27(21). 3518–3525. 200 indexed citations
7.
Richardson, Paul G., Pieter Sonneveld, Michael W. Schuster, et al.. (2009). Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline. British Journal of Haematology. 144(6). 895–903. 232 indexed citations
8.
Jagannath, Sundar, Bart Barlogie, James R. Berenson, et al.. (2008). Updated survival analyses after prolonged follow‐up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. British Journal of Haematology. 143(4). 537–540. 75 indexed citations
9.
Niesvizky, Rubén, Paul G. Richardson, S. Vincent Rajkumar, et al.. (2008). The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. British Journal of Haematology. 143(1). 46–53. 73 indexed citations
10.
Sezer, Orhan, David H. Vesole, Seema Singhal, et al.. (2006). Bortezomib-Induced Tumor Lysis Syndrome in Multiple Myeloma. Clinical Lymphoma & Myeloma. 7(3). 233–235. 42 indexed citations
11.
Lonial, Sagar, Edmund K. Waller, Paul G. Richardson, et al.. (2005). Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 106(12). 3777–3784. 263 indexed citations
12.
Orlowski, Robert Z., Thomas E. Stinchcombe, Beverly S. Mitchell, et al.. (2002). Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies. Journal of Clinical Oncology. 20(22). 4420–4427. 586 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sarah Waheed Breakdown of academic impact, for papers by Halyna Pylypenko Breakdown of academic impact, for papers by Annamaria Brioli Breakdown of academic impact, for papers by Martin Kropff Breakdown of academic impact, for papers by Andrew Cakana Breakdown of academic impact, for papers by William Deraedt Breakdown of academic impact, for papers by Anuj Mahindra Breakdown of academic impact, for papers by Leonard T. Heffner Breakdown of academic impact, for papers by Huaibao Feng Breakdown of academic impact, for papers by Andrea Freeman
Rankless by CCL
2026